BUZZ - UBS downgrades Besi rating to "Sell" due to risk from hybrid bonds, stock price plunges
路透社2026/10/07 08:36On October 7, BE Semiconductor Industries (BESI.AS) shares fell approximately 6% after UBS downgraded the Dutch chip equipment manufacturer from "Buy" to "Sell" and cut its target price by 57% to 159 euros. UBS stated that the expected demand for chip packaging technology "hybrid bonding" (HB)—the core of Besi's investment logic—"has not materialized as anticipated." UBS believes that because AI accelerator customers prioritize capacity expansion over performance improvements, the adoption rate of hybrid bonding technology in high-bandwidth memory will slow down. UBS expects that by 2028, hybrid bonding technology will account for 10% of equipment demand, whereas the market consensus suggests a figure of about 50%. The bank anticipates Besi's HB revenue in 2027-28 to be 50%-60% lower than consensus, and demand from co-packaged optics, AI accelerators, and PC processors is unlikely to fill the gap. UBS also noted that existing capacity at TSMC 2330.TW and Intel INTC.O is already sufficient to support "considerable shipment volumes," leaving limited upside unless adoption rates exceed expectations. Besi's share price extended Tuesday's losses, following a 5.4% drop after Bank of America Global Research downgraded the stock based on similar concerns. (link) (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to the potential for errors or lack of required context in automated translations, Reuters does not guarantee the accuracy of these texts, which are provided solely for readers’ convenience. Reuters assumes no liability for any damages or losses resulting from the use of these automated translation functions.)
October 7 - ** BE Semiconductor Industries (BESI.AS) shares fell about 6% after UBS downgraded the Dutch chip equipment maker from “buy” to “sell” and cut its price target by 57% to €159
** UBS said that demand expectations for the chip packaging technology “hybrid bonding” (HB)—the core of Besi’s investment thesis—“have not materialized as expected”
** UBS believes adoption of hybrid bonding technology in high-bandwidth memory will slow as AI accelerator customers are prioritizing capacity expansion over performance improvement
** UBS projects that by 2028, hybrid bonding technology will account for 10% of equipment demand, while market consensus implies about 50%
** The bank expects Besi’s HB revenue in 2027–28 to be 50%-60% lower than market consensus and demand from co-packaged optics, AI accelerators, and PC processors is unlikely to make up this shortfall
** UBS said the existing capacity of TSMC 2330.TW and Intel INTC.O is already sufficient to support “significant shipment volumes”; unless adoption exceeds expectations, there is limited upside
** Besi shares extended Tuesday’s losses, after Bank of America Global Research also downgraded the stock on similar concerns; shares ended Tuesday down 5.4% (link)
(To assist non-English speakers, Reuters has automatically translated its news reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters makes no guarantee regarding the accuracy of the automated translation. It is provided solely for the convenience of readers. Reuters assumes no responsibility for any harm or loss resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Indian Rupee: Gradual tightening path after RBI hike – ING
BUZZ – Lipocine shares soar after Canada approves its testosterone replacement therapy
October 7 - ** Pharmaceutical company Lipocine (LPCN.O) saw its stock price rise 28% in pre-market trading to $2.7. ** Lipocine announced that (link) it has received approval from Health Canada for its oral testosterone replacement therapy drug, Tlando, for the treatment of male hypogonadism. ** In January 2024, Lipocine licensed the commercialization rights for Tlando in the US and Canada to the private company Verity Pharma. ** Lipocine is eligible to receive milestone payments of up to $259 million, as well as royalties ranging from 12% to 18% based on Tlando’s net sales. ** According to Lipocine, over 700,000 prescriptions for testosterone replacement therapy (TRT) are issued annually in Canada, with approximately 50% of patients reimbursed through private insurance. ** TRT is available in multiple formulations, including injections, oral medications, and topical gels. ** As of the previous trading session’s close, LPCN shares had declined by 73% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translations may be inaccurate or lack desired context, Reuters does not guarantee the accuracy of translated content and provides such translations for user convenience only. Reuters accepts no responsibility for any harm or loss resulting from the use of automated translation features.)
BUZZ - H&P shares rise after drilling automation partnership with ExxonMobil
On October 7th, shares of the oilfield services company Helmerich & Payne (HP.N) rose 2% in pre-market trading to $40.4. H&P announced plans to deploy seven additional FlexRobotics systems for ExxonMobil (XOM.N) over the next 12 months. FlexRobotics is HP’s automated drilling platform technology. The company expects its operating margin to improve in fiscal year 2027 and reported strong performance in the fourth quarter. H&P remains committed to reducing its leverage ratio by the end of fiscal year 2027. As of the previous trading day’s close, the stock had risen 38.1% year-to-date. (For convenience, Reuters provides automated translations of its reports into several other languages. Automated translations may contain errors or not include the required context. Reuters does not guarantee the accuracy of automated translations and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translation features.)
BUZZ - Roblox shares fall after Google and Unity announce the launch of an AI-powered game creation platform
On October 7 – After Google and Unity announced the launch of a new AI gaming platform (link), the share price of gaming platform Roblox (RBLX.N) dropped 4.8% in pre-market trading to $43.39. The platform jointly developed by Google (GOOGL.O) and Unity (U.N) allows users to generate and customize playable games using only text prompts, without programming. Roblox has been expanding its own AI creation suite (link), including the introduction of the "Build" text-to-game tool in July, as well as other generative AI features added for developers in September. As of the previous trading day's close, RBLX had fallen roughly 44% year-to-date. (For the convenience of non-English speakers, Reuters has automated translation of its reports into multiple languages. Since automated translation may contain errors or lack the required context, Reuters does not guarantee the accuracy of automated translations and provides them for the convenience of readers only. Reuters bears no liability for any damages or losses arising from the use of automated translation.)
Crypto prices
More
